ACADIA Pharmaceuticals Announces FDA Priority Review of NUPLAZID™ (Pimavanserin) New Drug Application for Parkinson’s Disease Psychosis

Go back to ACADIA Pharmaceuticals Announces FDA Priority Review of NUPLAZID™ (Pimavanserin) New Drug Application for Parkinson’s Disease Psychosis

Acadia Pharma (ACAD) NUPLAZID NDA Accepted for Review; 05/01/16 PDUFA Date Set

November 2, 2015 8:12 AM EST

Acadia Pharma (NASDAQ: ACAD) announced that the New Drug Application (NDA) for NUPLAZID (pimavanserin) has been accepted for review by the U.S. Food and Drug Administration (FDA) and the agency has granted it Priority Review. ACADIA is seeking FDA approval of NUPLAZID for the treatment of psychosis associated with Parkinsons disease. The FDA granted NUPLAZID Breakthrough Therapy designation for this indication in 2014.

The FDA grants Priority Review to drugs that may offer major... More